Clinical Summary: The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States
Many patients with major depressive disorder do not respond after multiple antidepressant trials, and the downstream burden extends well beyond clinic visits to lost work and unemployment. This analysis quantifies how much treatment-resistant depression accounts for the national burden of medication-treated MDD in the United States, showing that a minority of patients drive a disproportionate share of costs.
Key Findings
- The annual prevalent population of individuals with medication-treated MDD included 8.95 million adults, of whom 2.76 million (30.9%) had TRD and 6.19 million (69.1%) had non-TRD MDD.
- The total annual incremental burden incurred by adults with medication-treated MDD relative to those without MDD was $92.7 billion, including $45.5 billion (49.1%) in health care costs, $28.8 billion (31.1%) in productivity costs, and $18.3 billion (19.8%) in unemployment costs.
- Adults with TRD accounted for $43.8 billion (47.2%) of the incremental costs of medication-treated MDD despite representing 30.9% of adults with medication-treated MDD.
- The weighted mean annual per-person incremental health care cost across US payers was $9,323 for adults with TRD and $3,197 for those with non-TRD MDD relative to those without MDD; extrapolated nationally, TRD contributed 56.6% of the $45.5 billion excess health care cost burden.
- The weighted mean annual per-person incremental productivity cost was $6,727 for employees with TRD and $5,763 for those with non-TRD MDD, and the weighted mean annual incremental unemployment rate was 8.0 versus 3.9 percentage points relative to those without MDD.
Treatment-resistant depression imposes a disproportionately high economic burden: 30.9% of adults with medication-treated MDD accounted for 47.2% of the total incremental cost burden and 56.6% of excess health care costs. In practice, earlier recognition and more effective management of TRD are high-yield targets for reducing both clinical and societal burden.
Practice Implications
- When patients require a third antidepressant treatment course after 2 antidepressant courses of adequate dose and duration, recognize that this TRD group carries substantially higher annual per-person health care costs ($9,323 vs $3,197) and warrants closer treatment planning.
- Discuss functional burden explicitly, not just symptom burden: compared with those without MDD, employees with TRD had $6,727 in annual incremental productivity costs and an 8.0 percentage point incremental unemployment rate.
- Health systems and payers should expect TRD prevalence to vary by coverage type, ranging from 21.4% in Medicare to 44.2% in Medicaid, when planning service needs and comparing populations.
- Because nearly half of the $92.7 billion burden of medication-treated MDD came from TRD ($43.8 billion), prioritizing pathways that improve outcomes in treatment-resistant cases is likely to have outsized economic impact.
